SG11201408011SA - Synthesis of antiviral compound - Google Patents
Synthesis of antiviral compoundInfo
- Publication number
- SG11201408011SA SG11201408011SA SG11201408011SA SG11201408011SA SG11201408011SA SG 11201408011S A SG11201408011S A SG 11201408011SA SG 11201408011S A SG11201408011S A SG 11201408011SA SG 11201408011S A SG11201408011S A SG 11201408011SA SG 11201408011S A SG11201408011S A SG 11201408011SA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- foster city
- gilead
- international
- lakeside drive
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 229940126656 GS-4224 Drugs 0.000 abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655935P | 2012-06-05 | 2012-06-05 | |
| US13/800,202 US9056860B2 (en) | 2012-06-05 | 2013-03-13 | Synthesis of antiviral compound |
| PCT/US2013/044148 WO2013184702A1 (en) | 2012-06-05 | 2013-06-04 | Synthesis of antiviral compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408011SA true SG11201408011SA (en) | 2015-01-29 |
Family
ID=49671039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408011SA SG11201408011SA (en) | 2012-06-05 | 2013-06-04 | Synthesis of antiviral compound |
Country Status (17)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004253860B2 (en) | 2003-05-30 | 2009-06-11 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
| AP2014007575A0 (en) | 2011-09-16 | 2012-04-30 | Gilead Pharmasset Llc | Methods for treating HCV |
| US9056860B2 (en) * | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
| US8969588B2 (en) | 2012-06-05 | 2015-03-03 | Gilead Pharmasset Llc | Solid forms of an antiviral compound |
| MD4595B1 (ro) | 2013-01-31 | 2018-10-31 | Gilead Pharmasset Llc. | Tabletă combinată conţinând doi compuşi antivirali |
| CN104211565A (zh) * | 2013-05-31 | 2014-12-17 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| EP2883876A1 (en) * | 2013-12-16 | 2015-06-17 | Actelion Pharmaceuticals Ltd. | Stereoselective synthesis of substituted pyrrolidines |
| TWI679203B (zh) | 2014-06-11 | 2019-12-11 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| CN104513147B (zh) * | 2014-11-20 | 2016-05-11 | 上海众强药业有限公司 | 芴乙酮衍生物的制备方法 |
| CN104513223B (zh) * | 2014-11-20 | 2017-07-14 | 上海众强药业有限公司 | 芴乙酮衍生物的制备方法 |
| US20180009790A1 (en) * | 2014-12-24 | 2018-01-11 | Prasad Raju Vnkv Vetukuri | An improved process for the preparation of hcv inhibitor |
| CN104530016A (zh) * | 2014-12-25 | 2015-04-22 | 上海泓博智源医药技术有限公司 | 一种雷迪帕韦的制备方法及其中间体 |
| CN107427495A (zh) | 2015-02-13 | 2017-12-01 | 桑多斯股份公司 | 包含雷迪帕韦和索非布韦的药物组合物 |
| WO2016145269A1 (en) | 2015-03-12 | 2016-09-15 | Teva Pharmaceuticals International Gmbh | Solid state forms ledipasvir and processes for preparation of ledipasvir |
| CN104829599B (zh) * | 2015-03-17 | 2017-06-09 | 上海众强药业有限公司 | 雷迪帕韦及其衍生物的制备方法及用于制备雷迪帕韦的中间体化合物 |
| CN104788361B (zh) * | 2015-04-21 | 2017-06-30 | 杭州科巢生物科技有限公司 | 5‑氮杂螺[2.4]庚烷‑6‑甲酸衍生物的合成方法 |
| WO2016199049A1 (en) * | 2015-06-09 | 2016-12-15 | Hetero Research Foundation | Process for the preparation of ledipasvir |
| CN104926796A (zh) * | 2015-06-17 | 2015-09-23 | 南通常佑药业科技有限公司 | 一种新的ns5a抑制剂药物的制备方法 |
| WO2016207915A1 (en) * | 2015-06-26 | 2016-12-29 | Mylan Laboratories Limited | Process for the preparation of ledipasvir |
| CN105017228A (zh) * | 2015-07-03 | 2015-11-04 | 上海众强药业有限公司 | 一种雷迪帕韦中间体单硫酸盐、其晶型及其制备方法 |
| CN104961733B (zh) * | 2015-07-06 | 2019-04-09 | 上海众强药业有限公司 | 雷迪帕韦晶型及其制备方法 |
| KR101919194B1 (ko) | 2015-09-15 | 2018-11-15 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
| CN105237516B (zh) * | 2015-10-13 | 2018-01-02 | 厦门市蔚嘉化学科技有限公司 | 一种雷迪帕韦的制备方法 |
| CN105399657B (zh) * | 2015-10-21 | 2017-10-10 | 海门慧聚药业有限公司 | 雷迪帕韦关键中间体的制备 |
| WO2017072596A1 (en) * | 2015-10-26 | 2017-05-04 | Optimus Drugs (P) Ltd | An improved process for the preparation of ledipasvir |
| CN105237384B (zh) * | 2015-11-06 | 2017-06-30 | 上海万溯化学有限公司 | 一种多取代芴衍生物的制备方法 |
| CN106892905A (zh) * | 2015-12-17 | 2017-06-27 | 常州市勇毅生物药业有限公司 | 一种雷迪帕韦的制备方法 |
| EP3411369A1 (en) | 2016-02-01 | 2018-12-12 | Lupin Limited | Process for the preparation of ledipasvir and intermediates thereof |
| WO2017145028A1 (en) * | 2016-02-26 | 2017-08-31 | Glenmark Pharmaceuticals Limited | Process for preparation of ledipasvir |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017195147A1 (en) | 2016-05-12 | 2017-11-16 | Lupin Limited | Process for the preparation of ledipasvir and intermediates thereof |
| CN106008316B (zh) * | 2016-06-17 | 2018-04-27 | 成都百事兴科技实业有限公司 | 一种合成雷迪帕韦手性中间体的方法 |
| CN105968040B (zh) * | 2016-06-29 | 2019-02-05 | 爱斯特（成都）生物制药股份有限公司 | 一种雷迪帕韦中间体的制备方法 |
| CN107641081A (zh) * | 2016-07-22 | 2018-01-30 | 江苏威凯尔医药科技有限公司 | 一种药物中间体的制备方法 |
| CN106349229B (zh) * | 2016-08-25 | 2018-11-06 | 安徽华昌高科药业有限公司 | 雷迪帕韦中间体的制备方法及中间体化合物 |
| CN106632275B (zh) * | 2016-12-20 | 2018-03-06 | 上海同昌生物医药科技有限公司 | 一种雷迪帕韦的制备方法及制备雷迪帕韦的中间体 |
| US10392370B2 (en) | 2017-03-13 | 2019-08-27 | Optimus Drugs Pvt Ltd | Process for the preparation of Daclatasvir dihydrochloride and its intermediates |
| CN107488685A (zh) * | 2017-06-13 | 2017-12-19 | 南京方生和医药科技有限公司 | (s)‑5‑氮杂螺环[2.4]庚烷‑6‑羧酸及其衍生物的酶化学制备方法 |
| EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION |
| CN107879908A (zh) * | 2017-11-14 | 2018-04-06 | 安徽诺全药业有限公司 | 一种雷迪帕维关键中间体及其制备方法 |
| CN107954990A (zh) * | 2017-11-14 | 2018-04-24 | 安徽诺全药业有限公司 | 一种雷迪帕维的制备方法 |
| CN108753863A (zh) * | 2018-06-14 | 2018-11-06 | 慎终（上海）生物科技有限公司 | 雷迪帕韦中间体的合成工艺 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| WO2020077071A1 (en) * | 2018-10-10 | 2020-04-16 | Forma Therapeutics, Inc. | Inhibiting fatty acid synthase (fasn) |
| EP3885339A1 (en) * | 2020-03-27 | 2021-09-29 | Rottapharm Biotech S.r.l. | Process for the preparation of (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof |
| CN112851545B (zh) * | 2020-07-08 | 2022-09-20 | 日照巴洛特药业有限公司 | 一种雷迪帕韦中间体的合成工艺 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150524A0 (en) * | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| TWI410422B (zh) * | 2007-01-15 | 2013-10-01 | Mitsubishi Tanabe Pharma Corp | 縮合四氫喹啉衍生物及其醫藥用途 |
| CN102007122B (zh) * | 2008-02-13 | 2013-09-04 | 百时美施贵宝公司 | 作为丙型肝炎病毒抑制剂的咪唑基联苯基咪唑 |
| US8232409B2 (en) * | 2008-10-15 | 2012-07-31 | Janssen Pharmaceutica N.V. | Heterocyclic benzimidazoles as TRPM8 modulators |
| PL2430014T3 (pl) | 2009-05-13 | 2016-02-29 | Gilead Pharmasset Llc | Związki przeciwwirusowe |
| EP2475256A4 (en) * | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US9296698B2 (en) * | 2009-11-23 | 2016-03-29 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| US20110306541A1 (en) | 2010-06-10 | 2011-12-15 | Gilead Sciences, Inc. | Methods for treating hcv |
| US8969588B2 (en) | 2012-06-05 | 2015-03-03 | Gilead Pharmasset Llc | Solid forms of an antiviral compound |
| US9056860B2 (en) * | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
-
2013
- 2013-03-13 US US13/800,202 patent/US9056860B2/en active Active
- 2013-06-04 CN CN201710524415.2A patent/CN107266428A/zh active Pending
- 2013-06-04 KR KR1020147036884A patent/KR102206434B1/ko active Active
- 2013-06-04 HK HK15109928.1A patent/HK1209124A1/xx unknown
- 2013-06-04 WO PCT/US2013/044148 patent/WO2013184702A1/en active Application Filing
- 2013-06-04 JP JP2015516145A patent/JP6181169B2/ja active Active
- 2013-06-04 SG SG11201408011SA patent/SG11201408011SA/en unknown
- 2013-06-04 BR BR112014030365A patent/BR112014030365A2/pt active Search and Examination
- 2013-06-04 AU AU2013271772A patent/AU2013271772B2/en active Active
- 2013-06-04 PT PT137292082T patent/PT2855454T/pt unknown
- 2013-06-04 KR KR1020207015492A patent/KR20200066376A/ko not_active Ceased
- 2013-06-04 ES ES13729208.2T patent/ES2587782T3/es active Active
- 2013-06-04 CN CN201380029806.7A patent/CN104520293B/zh active Active
- 2013-06-04 RU RU2014150435A patent/RU2636943C2/ru not_active IP Right Cessation
- 2013-06-04 CA CA2875508A patent/CA2875508C/en active Active
- 2013-06-04 IN IN2496MUN2014 patent/IN2014MN02496A/en unknown
- 2013-06-04 MX MX2014014569A patent/MX350892B/es active IP Right Grant
- 2013-06-04 EP EP13729208.2A patent/EP2855454B1/en active Active
-
2014
- 2014-11-27 IL IL235941A patent/IL235941B/en not_active IP Right Cessation
-
2015
- 2015-05-05 US US14/704,627 patent/US20150232453A1/en not_active Abandoned
- 2015-10-12 HK HK18104959.1A patent/HK1245273A1/zh unknown
-
2016
- 2016-08-04 US US15/228,825 patent/US9718807B2/en active Active
-
2017
- 2017-06-14 JP JP2017116558A patent/JP6356876B2/ja active Active
-
2018
- 2018-03-25 IL IL258327A patent/IL258327A/en unknown
- 2018-06-14 JP JP2018113637A patent/JP6594487B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408011SA (en) | Synthesis of antiviral compound | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201408013WA (en) | Solid forms of an antiviral compound | |
| SG11201407596TA (en) | Conjugation reagents | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201408047XA (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201408064PA (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201408261UA (en) | Syringe | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407774XA (en) | Conversion of biomass | |
| SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
| SG11201407115XA (en) | Carboxylic acid compounds | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201408045UA (en) | MACROCYCLIC INHIBITORS OF <i>FLAVIVIRIDAE</i> VIRUSES | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201407189XA (en) | C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity | |
| SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
| SG11201406888QA (en) | Lysin-glutamic acid dipeptide derivatives | |
| SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |